A patient diagnosed with schizophrenia had an exacerbation of hallucinations and delusions related to medication non-adherence and was hospitalized for 10 days. The patient is stabilized and discharge is planned. The patient’s family is concerned that the patient’s symptoms will return after discharge. Acting as an advocate for the patient’s rights, the nurse’s best response is:

Choice A reason: Decreasing dopamine is used for disorders like schizophrenia, where excess mesolimbic dopamine causes hallucinations. Memory difficulties, often linked to Alzheimer’s, involve cholinergic deficits, not dopamine excess. Reducing dopamine could worsen cognition by disrupting reward and attention pathways, making this approach scientifically inappropriate for memory issues.

Choice B reason: Inhibiting GABA production is irrelevant for memory. GABA regulates neural inhibition, and its reduction could increase excitability, worsening conditions like seizures. Memory deficits, particularly in dementia, stem from reduced acetylcholine in the hippocampus, not GABA, making this option misaligned with the neurobiology of memory impairment.

Choice C reason: Preventing acetylcholine destruction, via cholinesterase inhibitors, enhances cholinergic activity in the hippocampus and cortex, critical for memory in conditions like Alzheimer’s. Low acetylcholine levels impair neural signaling, causing memory deficits. This approach directly addresses the neurochemical basis of memory difficulties, making it scientifically appropriate for treatment.

Choice D reason: Increasing dopamine sensitivity is relevant for disorders like Parkinson’s, not memory deficits. Dopamine affects motivation and movement, not memory, which relies on acetylcholine in the hippocampus. Enhancing dopamine could disrupt cognitive balance, worsening memory without addressing the cholinergic deficits central to memory impairment.

Choice A reason: Serotonin modulates mood and anxiety but is not primarily linked to schizophrenia’s core symptoms. While serotonin imbalances contribute to depression, schizophrenia’s hallucinations and delusions stem from dopamine hyperactivity in the mesolimbic pathway, making serotonin an incorrect choice for this disorder’s pathophysiology.

Choice B reason: GABA inhibits neural activity, and its dysfunction is linked to anxiety or seizures, not schizophrenia’s positive symptoms. Schizophrenia involves dopamine excess in the mesolimbic pathway, not GABA deficits. GABA’s role is secondary, making it an inaccurate choice for explaining hallucinations and delusions.

Choice C reason: Dopamine hyperactivity in the mesolimbic pathway causes hallucinations, delusions, and bizarre behavior in schizophrenia. Excess dopamine signaling disrupts cognitive and perceptual processes, leading to positive symptoms. Antipsychotics target D2 receptors to reduce these effects, confirming dopamine’s central role in schizophrenia’s pathophysiology.

Choice D reason: Acetylcholine is involved in memory and attention, not schizophrenia’s core symptoms. While cholinergic deficits occur in dementia, schizophrenia’s hallucinations and delusions are driven by dopamine dysregulation, not acetylcholine. This makes acetylcholine an incorrect choice for the neurotransmitter associated with these symptoms.